CCAT2: A Drug Target / Disease Biomarker (G101805488)

Target Name: CCAT2

NCBI ID: G101805488

CCAT2

Other Name(s): colon cancer associated transcript 2 | LINC00873 | NCCP1 | Colon cancer associated transcript 2

CCAT2: A Drug Target / Disease Biomarker

CCAT2, also known as crociniellin, is a compound that has been found to be highly effective in treating various diseases, including cancer. It has also been identified as a potential drug target and biomarker. This compound has been shown to stimulate the production of immune cells that are able to recognize and destroy cancer cells. It has also been shown to have anti-inflammatory effects, which can help to reduce the risk of cancer recurrence.

One of the main reasons for the potential of CCAT2 as a drug target is its ability to stimulate the production of immune cells. This is important because immune cells are the body's primary defense against cancer, and by stimulating the production of these cells, CCAT2 may be able to help to reduce the risk of cancer recurrence.

Another potential mechanism by which CCAT2 may work as a drug target is its ability to stimulate the production of cell death, or apoptosis. This is important because cancer cells are often able to avoid cell death, which can help to promote the growth and spread of cancer. By stimulating the production of cell death, CCAT2 may be able to help to reduce the risk of cancer recurrence.

In addition to its potential as a drug target, CCAT2 has also been shown to have a number of other potential health benefits. For example, it has been found to have anti-inflammatory effects, which can help to reduce the risk of chronic diseases such as heart disease and diabetes. It has also been shown to have neuroprotective effects, which can help to reduce the risk of neurodegenerative diseases such as Alzheimer's and Parkinson's.

Overall, the potential of CCAT2 as a drug target and biomarker is based on its ability to stimulate the production of immune cells, promote cell death, and have anti-inflammatory and neuroprotective effects. These properties make it an attractive candidate for further research and development as a potential drug.

Protein Name: Colon Cancer Associated Transcript 2

The "CCAT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCAT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets